A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Study Identifier
192024-082
CT.gov Identifier
NCT01863953
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • Fixed-Combination Bimatoprost/Brimonidine
  • Bimatoprost Ophthalmic Solution 0.01%
  • Vehicle Ophthalmic Solution
  • Brimonidine Tartrate Ophthalmic Solution 0.2%
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    40+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of ocular hypertension or glaucoma * Requires intraocular pressure (IOP)-lowering therapy
    Exclusion Criteria:
    * Cataract surgery in one eye * Ocular laser or intraocular surgery within 6 months * Refractive surgery in either eye * Anticipated use of contact lenses during the study * Expected use of artificial tears during the study

    Protocol Summary

    This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable